Page 1

MEDIVIR MEDIVIR AB – INTERIM REPORT - JANUARY - JUNE 2026 " With three Phase II studies funded , FLEX - HCC recruitment on track , and MIV - 711 expanded into a second rare bone indication , Medivir is in its strongest position in many years " April - June Financial summary for the quarter • • Net turnover amounted to SEK 1.2 ( 1.5 ) million . Earnings before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -21.2 ( - 22.5 ) million . Basic and diluted earnings per share amounted to SEK -0.04 ( -0.20 ) . • Cash flow from operating activities amounted to SEK -18.3 ( -26.2 ) million . • Cash and cash equivalents at the end of the period amounted to SEK 253.5 ( 38.2 ) million . Significant events during the quarter • • • • At the Annual General Meeting on May 7 , Anders Hallberg ( Chairman ) , Angelica Loskog and Anna Törner were re - elected as board members . Kristian Tryggvason was newly elected . In May , the first patient was included in FLEX - HCC , the randomized phase 2 study of fostrox + lenvatinib compared with lenvatinib in second - line advanced liver cancer . In June , the phase 1b / 2a results for fostrox + lenvatinib were published in Clinical Cancer Research . In June , the Board resolved on a directed share issue of approximately SEK 140 million , primarily to finance clinical development of MIV - 711 in Legg- Calvé - Perthes disease ( Perthes disease ) . January - June Financial summary for the period • • Net turnover amounted to SEK 2.3 ( 2.1 ) million . Earnings before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -29.9 ( - 35.1 ) million . Basic and diluted earnings per share amounted to SEK -0.06 ( -0.32 ) . • Cash flow from operating activities amounted to SEK -31.3 ( -53.0 ) million . Cash and cash equivalents at the end of the period amounted to SEK 253.5 ( 38.2 ) million . Significant events after the end of the period • • • At the Extraordinary General Meeting on July 20 , the issue of 6,097,560 ordinary shares to Hallberg Management AB ( Tranche 2 ) was approved , completing the SEK 140 million directed share issue . In July , Medivir received a Notice of Allowance from the USPTO for the combination patent covering fostrox plus lenvatinib in hepatocellular carcinoma ( HCC ) and liver metastases . Once granted , it provides protection and market exclusivity until at least April 2041 . As of July 31 , 2026 , Medivir had 626,487,237 shares in total , of which 624,037,074 were ordinary shares and 2,450,163 were C shares . Medivir in brief Medivir develops innovative therapies targeting areas of high unmet medical need . Its drug candidates focus on indications where current treatment options are limited or non - existent , offering the potential to deliver meaningful improvements for patients . Medivir's two lead programs are fostrox , a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects , and MIV - 711 , aimed at treating Osteogenesis Imperfecta ( brittle bone disease ) and Perthes disease ( idiopathic degeneration of the femoral head in children ) . Both candidates have blockbuster potential , representing significant value creation opportunities for Medivir's shareholders and affected patients . Collaborations play a key role in Medivir's business model , with drug development conducted either in - house or in partnership . Medivir ( Nasdaq Stockholm : MVIR ) is listed on the Small Cap segment of Nasdaq Stockholm . More information is available at www.medivir.com Medivir AB ( publ ) , 556238-4361 . Lunastigen 5 , SE - 141 44 Huddinge . Telephone : +46 ( 0 ) 8-546 831 00 . info@medivir.se | www.medivir.com 1